Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT02490735
PHASE2

CIK in Treating Patients With Esophageal Cancer

Sponsor: The First People's Hospital of Changzhou

View on ClinicalTrials.gov

Summary

Chemotherapy is the main treatment method for patients with Esophageal Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from growing. A series of studies reported that cytokine-induced killer cells (CIK) have a broad anti-tumor spectrum. The investigators suppose that CIK will improve the prognosis. Combining chemotherapy with biological therapy may kill more tumor cells. In this study, the patients will be treated with CIK cells after chemotherapy. The purpose of this study is to evaluate the efficacy of CIK for Esophageal Cancer.

Official title: A Randomized Controlled Study of Cytokine-induced Killer Cells (CIK) Treatment in Patients With Staging Ⅰ-Ⅲ of Esophageal Carcinoma

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

2000

Start Date

2015-08

Completion Date

2042-08

Last Updated

2015-07-07

Healthy Volunteers

No

Interventions

BIOLOGICAL

Cytokine-induced Killer Cells

chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment